NASDAQ:PSTV Plus Therapeutics Q2 2026 Earnings Report $3.90 -0.18 (-4.41%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$3.93 +0.03 (+0.77%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Plus Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.88Beat/MissN/AOne Year Ago EPSN/APlus Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.11 millionBeat/MissN/AYoY Revenue GrowthN/APlus Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateFriday, August 14, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Plus Therapeutics Earnings HeadlinesPlus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay PlatformJuly 16 at 7:30 AM | globenewswire.comPlus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases MonitoringJuly 14 at 7:30 AM | globenewswire.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.July 17 at 1:00 AM | American Alternative (Ad)Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Consensus Recommendation of "Hold" by BrokeragesJuly 9, 2026 | americanbankingnews.comPlus Therapeutics (NASDAQ:PSTV) Trading Down 3.2% - What's Next?July 8, 2026 | americanbankingnews.comPlus Therapeutics Inc.July 2, 2026 | barrons.comSee More Plus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email. Email Address About Plus TherapeuticsPlus Therapeutics (NASDAQ:PSTV) is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases. The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors. Plus Therapeutics has secured orphan drug and rare pediatric disease designations for select compounds, reflecting its focus on addressing unmet needs in both adult and pediatric oncology. Clinical studies are conducted in collaboration with academic medical centers and contract research organizations across North America. Headquartered in Austin, Texas, Plus Therapeutics is led by an executive team with extensive experience in radiopharmaceuticals and oncology drug development. The company maintains research, manufacturing and administrative operations in the United States and continues to expand strategic partnerships to advance its targeted radiotherapeutic portfolio.View Plus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetRevving Up Returns: Big Banks Race Through the Rate PlateauWhy Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the TestAI’s Power Crunch Fuels a Pivot for These 2 Oilfield StocksToast’s Comeback Story Is Getting Harder for Wall Street to IgnoreWhy Conagra’s Dividend Cut Could Be the Best Thing for InvestorsWhich Storage Stock Is Best Positioned to Win the AI Memory War? Upcoming Earnings HDFC Bank (7/18/2026)ICICI Bank (7/18/2026)General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
